MMCAP International’s Psyence Biomedical Warrant PBMWW Stock Holding History

MMCAP International’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.6K	Hold	600,000	–	–	﹤0.01%	272
2026 Q1	$10.9K	Hold	600,000	–	–	﹤0.01%	223
2025 Q4	$11.1K	Hold	600,000	–	–	﹤0.01%	188
2025 Q3	$15.1K	Hold	600,000	–	–	﹤0.01%	153
2025 Q2	$12.2K	Hold	600,000	–	–	﹤0.01%	127
2025 Q1	$10.1K	Hold	600,000	–	–	﹤0.01%	110
2024 Q4	$8.64K	Hold	600,000	–	–	﹤0.01%	118
2024 Q3	$7.56K	Hold	600,000	–	–	﹤0.01%	130
2024 Q2	$6.3K	Hold	600,000	–	–	﹤0.01%	150
2024 Q1	$42K	Buy	+600,000	New	+$37.4K	0.01%	94

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

MMCAP International's PBMWW Position: Q2 2026 in Review

MMCAP International held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 600,000 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #272.

MMCAP International first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $42K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

MMCAP International held 600,000 shares of Psyence Biomedical Warrant worth $14.6K as of Q2 2026.
MMCAP International left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of MMCAP International's portfolio in Q2 2026, its #272 holding.
MMCAP International first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
MMCAP International's Psyence Biomedical Warrant position peaked at $42K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on MMCAP International's 13F filing for Q2 2026, filed 14 Aug 2026.